LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.09 0.98

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.06

Max

3.16

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.62% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.8M

1.1B

Vorige openingsprijs

2.11

Vorige sluitingsprijs

3.09

Nieuwssentiment

By Acuity

50%

50%

164 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mrt 2026, 23:36 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mrt 2026, 23:35 UTC

Acquisities, Fusies, Overnames

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mrt 2026, 23:29 UTC

Winsten

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mrt 2026, 23:08 UTC

Marktinformatie

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

28.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  28.62%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

164 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat